Thyroid Disease and Dioxin Exposure: Phil Goodrum to Present at Dioxin 2018
August 23, 2018

Integral Senior Science Advisor Philip Goodrum, Ph.D., DABT, will present at the 38th International Symposium on Halogenated Persistent Organic Pollutants (POPs) & 10th International PCB Workshop: Dioxin 2018. Held in Kraków, Poland, on August 26–31, 2018, the symposium and workshop are recognized as the leading international POPs meeting for scientists and regulators.

On Tuesday, August 28, Dr. Goodrum will deliver a platform presentation titled “Use of Thyroid Disease Incidence and Dose-Response Analysis to Reduce Uncertainty in the Dioxin Oral Reference Dose.” Coauthored with Robert Budinsky of The Dow Chemical Company and Integral scientists Emma Mendelsohn and Heather Summers, this presentation will introduce an alternative method for quantifying a point of departure used in the calculation of an oral reference dose (RfD) for dioxin. The approach extends concepts regarding quantitative uncertainty analysis introduced in 2012 by the U.S. Environmental Protection Agency in response to recommendations from the National Academy of Sciences. The current RfD is based in part on estimates of changes in thyroid hormone levels in children born to mothers who were previously exposed to dioxin in Seveso, Italy. Dr. Goodrum will discuss how these data can be combined with robust data sets available from neonatal thyroid screening programs to more directly link changes in thyroid hormone levels with changes in the incidence rate of congenital hypothyroidism.

Learn more about Dioxin 2018.

A board-certified toxicologist with extensive experience with emerging contaminants, Dr. Goodrum has more than 25 years of experience in quantitative risk assessment and environmental modeling, specializing in applications to human health and ecological risk assessment, sediment remediation, groundwater compliance monitoring, and natural resource damage assessment.

For more information about this presentation and Integral’s related capabilities, contact Dr. Goodrum at